News
Qlaris Bio to showcase promising data on QLS-111, a novel glaucoma treatment, at the 2025 World Glaucoma Congress, ...
ADX-2191 is an investigational drug candidate from Aldeyra, for the treatment of primary vitreoretinal lymphoma (PVRL), a ...
New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients ...
ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair ...
FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema, ...
ForSight Robotics secures $125M to advance its robotic surgery platform, targeting cataract procedures and additional ...
Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.
Assistive devices empower patients with central vision loss to regain independence, enhancing daily activities and reducing ...
Funding will support continued product development, while the board is composed of “global leaders in posterior and anterior ...
Q&A: Kira Manusis, MD, on how the Center for Refractive Solutions is redefining patient care at NYEE
As its director, Manusis outlines the facility’s role in delivering advanced, personalized solutions to improve vision and ...
To conduct the study, the investigators obtained data on coffee consumption from genome‐wide association studies (GWAS) and ...
From laser vision correction to adjustable lens implants, the Center for Refractive Solutions at New York Eye and Ear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback